Here’s a startling fact: Neuromyelitis Optica Spectrum Disorder (NMOSD) remains one of the most perplexing neuroimmunologic conditions for clinicians, yet its complexities are often overlooked. But here’s where it gets controversial—despite advancements, the line between NMOSD and conditions like MOGAD or MS is still blurred, leaving room for misdiagnosis. In a recent discussion, Elena Grebenciucova, MD, assistant professor of neurology at Northwestern University and a neuroimmunology expert, sheds light on the evolving landscape of NMOSD diagnosis and management. Her insights are a must-read for anyone navigating this challenging field.
NMOSD’s potential for severe relapses and its chameleon-like symptoms make it a clinical enigma. With the 2025 revisions to diagnostic criteria and a deeper understanding of seropositive and seronegative phenotypes, the field is in constant flux. And this is the part most people miss—updated guidelines emphasize the critical need for high-quality antibody testing and clinical vigilance to differentiate NMOSD from similar disorders. Dr. Grebenciucova’s conversation highlights practical challenges and emerging strategies, offering a lifeline for neurologists in their daily practice.
NeurologyLive®: For young clinicians entering neuroimmunology, what’s the first step in mastering NMOSD treatment?
Elena Grebenciucova, MD: The cornerstone is recognizing the clinical syndrome. Severe or bilateral optic neuritis should immediately trigger testing for aquaporin-4 (AQP4) and MOG antibodies. Here’s the kicker—even mild optic neuritis shouldn’t be dismissed; antibody testing is still crucial. Another common pitfall? Assuming cerebrospinal fluid (CSF) is the gold standard for testing. Serum testing, particularly with live cell–based assays, is the norm for AQP4 and MOG antibodies. These assays offer superior sensitivity and specificity, but timing matters—testing after immunotherapy like plasma exchange or rituximab can yield false negatives. Retesting in three to six months is often necessary, and clinicians must remain vigilant with suspected cases.
Controversial Question: Should ELISA testing be completely abandoned for NMOSD diagnosis? Dr. Grebenciucova argues yes, advocating for immediate retesting with live cell–based assays if ELISA was initially used.
Managing Seronegative NMOSD: The 2025 criteria now distinguish seropositive AQP4 NMOSD from what’s termed “seronegative NMOSD clinical syndromes.” Why? Because seronegative cases lack uniform biology, pathology, and treatment responses. This is where opinions diverge—are seronegative cases a single disease or a heterogeneous group? Dr. Grebenciucova leans toward the latter, emphasizing the need for diagnostic flexibility and tailored treatment approaches.
Long-Term Immunotherapy: For AQP4-positive NMOSD, long-term therapy is the norm, with FDA-approved options like complement inhibitors and anti–IL-6 therapy. However, de-escalation is tricky. Unlike MS, NMOSD relapses persist even in older patients, often with severe consequences. Here’s the debate—should therapy ever be stopped, or just switched? Dr. Grebenciucova rarely recommends stopping therapy entirely, opting instead for agents with better infection risk profiles in aging patients.
Special Populations: Pregnancy and coexisting autoimmune diseases add layers of complexity. Unlike MS, NMOSD increases relapse risk during pregnancy, yet clear guidelines are lacking. Similarly, overlapping conditions like lupus complicate treatment choices. The million-dollar question: How do NMOSD therapies interact with modern lupus medications? Ongoing research is critical to answering this.
Final Thought: As NMOSD diagnosis and management evolve, staying informed is non-negotiable. Subscribe to NeurologyLive for expert insights, breakthrough data, and treatment updates that keep you ahead in this dynamic field. What’s your take? Do you agree with Dr. Grebenciucova’s approach to seronegative NMOSD or long-term therapy? Share your thoughts in the comments—let’s spark a conversation!
